Feasibility and Accuracy of Circulating Tumor DNA (ctDNA) in Assessing Response to Chemotherapy, Prognostication, and Guiding Therapy in Ovarian Cancer: A Review of Literature and Future Directions
Oct 2026· Indian Journal of Gynecologic Oncology· Vol 24· 0 citations· 71 references
TL;DR
Current evidence supports ctDNA's role as a prognostic and molecular monitoring biomarker; however, routine clinical implementation should await robust prospective evidence demonstrating that ctDNA-guided therapeutic strategies improve clinically meaningful patient outcomes.
Simple Summary Recurrence remains a major challenge after treatment intended to cure colorectal cancer, as small amounts of residual cancer may remain below the detection limits of imaging and routine blood tests. This review examined 94 publications evaluating whether small fragments of genetic material shed by cancer...
Hannah Hyde, Emma Mageau, Chelsea M. Leduc et al.· Current Oncology· 0 citations
Circulating tumor DNA (ctDNA) has emerged as a potential paradigm-shifting biomarker for precision management of bladder cancer, particularly muscle-invasive bladder cancer (MIBC). Although ctDNA assays are not yet widely implemented in routine clinical practice, a growing body of evidence supports its utility in diagn...
S. S. Manivasagam, Fatemeh Sheikhsaran, Jay D. Raman et al.· Therapeutic Advances in Urol...· 0 citations
Continuous technological innovation, prospective multicenter validation, standardized testing protocols, and evidence-based clinical guidelines are essential to fully integrate ctDNA into routine precision breast cancer care.
E. I. Obeagu, C. Okafor· Breast Cancer: Basic and Cli...· 0 citations
The postoperative management of resectable solid tumors depends on clinicopathological risk stratification. However, these static criteria often fail to identify occult minimal residual disease (MRD), resulting in suboptimal adjuvant treatment characterized by either overtreatment or undertreatment. Circulating tumor D...
Ming-Chi Ma, B. Xia, Qian Xu et al.· Chinese journal of cancer re...· 0 citations
Despite advances in systemic therapy, many early breast cancer patients experience recurrence due to subclinical minimal residual disease (MRD). Circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) have emerged as promising liquid biopsy markers for post-treatment MRD detection. This pre-registered systemat...
E. Yousef, M. Elghnam, Hiba Elhassan et al.· International Journal of Mol...· 0 citations
Background: Circulating tumor DNA (ctDNA) has emerged as a potential marker of minimal residual disease (MRD) after resection of colorectal liver metastases (CRLM), but its prognostic value and possible role in guiding postoperative management remain uncertain. This systematic review evaluated the available evidence on...
M. Yerolatsite, N. Torounidou, Loizos Hadjigeorgiou et al.· Cancers· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
